Evaluation of MicroRNAs and Vitamin B12 Expression in Subjects with Neurologic Symptoms of Depression, Anxiety and Fatigue in Long COVID-19

At the moment, the number of people with long COVID is unkown because there is still no effective diagnosis. This is why is very important to analyze the most common symptoms, which are: depression, anxiety and fatigue. This project seeks to analyze some blood components of people with long COVID, such as microRNAs and vitamin B12, in order to identify the body processes that changed after COVID-19 and thereby design better therapies and diagnostic methods focused on each of them.

The hypothesis is that the expression of miR-21, -146a and -155 will be overexpressed as well as there will be a deficiency of vitamin B12 in serum in subjects suffering from long COVID with neurological symptoms of depression, anxiety and fatigue.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Long COVID Anxiety Disorders Behavior Behavioral Symptoms COVID-19 Chronic Disease Coronaviridae Infections Coronavirus Infections Depression Disease Attributes Fatigue Infections Long COVID Syndrome Lung Diseases Mental Disorders Nidovirales Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral Post-Acute COVID-19 Syndrome Post-Infectious Disorders RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Signs and Symptoms Virus Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Instituto Nacional de Rehabilitación

Mexico City, 14389, Mexico

Location status: Recruiting

Location contact

Alfonso Alfaro Rodriguez, Doctorado

CONTACT

[email protected]

55 5999 1000 ext. 19305

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects with confirmed diagnosis of COVID-19 by SARS-CoV-2 infection by PCR or antigen testing.
With presence of neurological symptoms of depression, anxiety and fatigue associated with COVID-19 after three months from the first day of acute infection symptoms.

Exclusion criteria

Subjects who have presented symptoms of acute infection in the last twelve weeks.
Subjects who present diagnostic premorbid neurological alterations.
Subjects who do not have at least 2 doses of COVID-19 vaccine, with last application date equal or older than 3 months.

Treatment and study plan

Primary outcomes

Change of microRNA expression between long COVID group and control group

Time frame: immediately after the blood extraction
Change of vitamin B12 concentration between long COVID group and control group

Time frame: immediately after the blood extraction
Link the expression of microRNAs with the score obtained in the instruments to evaluate depression, anxiety and fatigue

Time frame: immediately after the blood extraction
Link the concentration of vitamin B23 with the score obtained in the instruments to evaluate depression, anxiety and fatigue.

Time frame: immediately after the blood extraction

Sponsors and collaborators

Lead sponsor

Instituto Nacional de Rehabilitacion

Other Gov

Registry information

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Mar 7, 2025
Registry last updated: Mar 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting